ArticleNature communications2016
Large-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- An automated high-resolution screening platform identifies regulators of anchor cell invasion inScience advances · 2026Article
- Machine Learning-Accelerated Analysis ofResearch square · 2026Article
- A robust, high-content NAM for repeatable and predictive developmental and reproductive toxicity assessment in C. elegans.Scientific reports · 2026Article
- Application ofBiomolecules & therapeutics · 2026Review
- A Robust, High-Content NAM for Repeatable and Predictive Developmental and Reproductive Toxicity Assessment in C. elegans.Research square · 2026Article
- Impairment of neuronal activity occurs at the early stages of the aggregation cascade of Aβ1-42 and mutant Tau.Disease models & mechanisms · 2026Article
- High-Throughput Toxicity Screening withEnvironmental science & technology · 2026Review
- VAB-8/KIF26, LIN-17/Frizzled, and EFN-4/Ephrin control distinct stages of posterior neuroblast migration downstream of the MAB-5/Hox transcription factor in Caenorhabditis elegans.PLoS genetics · 2025Article
- Automated Platforms inMicromachines · 2025Review
- Dissection of Neurochemical Pathways Across Complexity and Scale.Journal of neurochemistry · 2025Review
- Utilization of Artificial Intelligence Coupled with a High-Throughput, High-Content Platform in the Exploration of Neurodevelopmental Toxicity of Individual and Combined PFAS.Journal of xenobiotics · 2025Article
- Machine learning-based analysis of microfluidic device immobilized C. elegans for automated developmental toxicity testing.Scientific reports · 2025Article
- Screening conditions and constructs for attempted genetic transformation of C. elegans by Agrobacterium.PloS one · 2025Article
- Automated multimodal imaging of Caenorhabditis elegans behavior in multi-well plates.Genetics · 2024Article
- vivoBodySeg: Machine learning-based analysis of C. elegans immobilized in vivoChip for automated developmental toxicity testing.Research square · 2024Article
- High-throughput light sheet imaging of adult and larvalRSC advances · 2024Article
- The effect of common paralytic agents used for fluorescence imaging on redox tone and ATP levels in Caenorhabditis elegans.PloS one · 2024Article
- OrganoidChip facilitates hydrogel-free immobilization for fast and blur-free imaging of organoids.Scientific reports · 2023Article
- Difference in Intestine Content ofMicromachines · 2023Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Next generation drug screening could benefit greatly from in vivo studies, using small animal models such as Caenorhabditis elegans for hit identification and lead optimization. Current in vivo assays can operate either at low throughput with high resolution or with low resolution at high throughput. To enable both high-throughput and high-resolution imaging of C. elegans, we developed an automated microfluidic platform. This platform can image 15 z-stacks of ∼4,000 C. elegans from 96 different populations using a large-scale chip with a micron resolution in 16 min. Using this platform, we screened ∼100,000 animals of the poly-glutamine aggregation model on 25 chips. We tested the efficacy of ∼1,000 FDA-approved drugs in improving the aggregation phenotype of the model and identified four confirmed hits. This robust platform now enables high-content screening of various C. elegans disease models at the speed and cost of in vitro cell-based assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.